Top 10 sessions to attend at ASH 2015

Article

Traveling to Orlando for ASH 2015? Make the most out of your trip by attending these presentations. View the top 10.

 

This year’s American Society of Hematology (ASH) Conference, held in Orlando, will feature a wide array of sessions. To help you nail down your schedule, Managed Healthcare Executive has identified 10 must-attend sessions.

View our Events Calendar to plan ahead for more upcoming events.

 

 

Pediatric Hematological Malignancies: Beyond Acute Lymphocytic Leukemia

Saturday, December 5, 9:30 a.m. - 11:00 a.m.
or
Saturday, December 5, 2:00 p.m. - 3:30 p.m.

This session will focus on recent advances in the pediatric malignant disorders beyond the most common acute lymphoblastic leukemia, such as acute myeloid leukemia, Hodgkin lymphoma, and a range of lymphoma subtypes. Session presenters are: E. Anders Kolb, MD, of the Alfred I. duPont Hospital for Children in Wilmington, Delaware; Kara M. Kelly, MD, of Columbia University Medical Center in New York, New York; and Rachel Kobos, MD, Memorial Sloan Kettering Cancer Center in New York, New York.

 

 

 

Multiple Advances in Myeloma

Saturday, December 5, 4:00 p.m. - 5:30 p.m.
or
Sunday, December 6, 7:30 a.m. - 9:00 a.m.

Presented by:
S. Vincent Rajkumar
Thierry Facon, MD
Sagar Lonial, MD

This session will share how treatment options for myeloma have rapidly progressed over the past decade. It will include a review of available evidence on the use of maintenance therapy in myeloma, and a review of the rationale for combination therapy in myeloma. Presenters are: S. Vincent Rajkumar, of the Mayo Clinic in Rochester, Minnesota; Thierry Facon, MD, of Lille University Hospital in Lille, France; and Sagar Lonial, MD, of the Winship Cancer Institute at Emory University in Atlanta, Georgia.

 

 

 

Patient-Reported Outcomes in Hematology

Sunday, December 6, 9:30 a.m. - 11:00 a.m.

or

Monday, December 7, 10:30 a.m. - 12:00 p.m.


Presented by:
David Cella, PhD
Virginia E. Kwitkowski, MS, ACNP-BC
Julie A. Panepinto, MD, MSPH

This session will focus on how patient-reported outcomes can be used to improve patient care. Session presenters are: David Cella, PhD, of Northwestern University in Chicago; Virginia E. Kwitkowski, MS, ACNP-BC, of FDA; and Julie A. Panepinto, MD, MSPH, of The Medical College of Wisconsin/Children's Research Institute of the Children's Hospital of Wisconsin in Milwaukee, Wisconsin.

 

 

 

 

Treatment of Acute Myeloid Leukemia: Moving Beyond 3 + 7

Saturday, December 5, 2:00 p.m. - 3:30 p.m.
or
Monday, December 7, 2:45 p.m. - 4:15 p.m.

Presented by:
Eytan M. Stein, MD
Roland B. Walter, MD, PhD, MS
Marcos J. de Lima, MD

This session will focus on recent attempts to improve on the results obtained with 3+7 based treatment. Items covered include using small molecule inhibitors, antigen-specific immunotherapies, and cellular therapies. Presenters are: Eytan M. Stein, MD, of Memorial Sloan Kettering Cancer Center in New York, New York; Roland B. Walter, MD, PhD, MS, of the University of Washington in Seattle, Washington; and Marcos J. de Lima, MD, of the University Hospitals and Case Western Reserve University in Cleveland, Ohio.

 

 

 

 

Update in Large Cell Lymphoma

Saturday, December 5, 7:30 a.m. - 9:00 a.m.
or
Saturday, December 5, 4:00 p.m. - 5:30 p.m.


Presented by:
Eric D. Hsi, MD
Jonathan W. Friedberg, MD
Silvia Montoto, MD

This session will focus on recent advances in large cell lymphoma with a focus on diagnostic and prognostic considerations and treatment options. Presenters are: Eric D. Hsi, MD, of the  Robert J. Tomsich Pathology & Laboratory Medicine Institute at the Cleveland Clinic in Cleveland, Ohio; Jonathan W. Friedberg, MD, of the University of Rochester in Rochester, New York; and Silvia Montoto, MD, of St Bartholomew's Hospital, Barts Health NHS Trust, in London.

 

 

 

 

Contemporary Therapy of Lymphoma

Saturday, December 5, 2:00 p.m. - 3:30 p.m.
or
Sunday, December 6, 9:30 a.m. - 11:00 a.m.

Presented by:
Philippe Armand, MD, PhD
Patrick J. Stiff, MD
Kristie A. Blum, MD

The session will provide insight on how best to incorporate new therapies for patients with B-cell lymphomas into the treatment paradigms. Presenters are: Philippe Armand, MD, PhD, of the Dana-Farber Cancer Institute at Harvard Medical School in Boston; Patrick J. Stiff, MD, of the Loyola University Medical Center in Maywood, Illinois; and Kristie A. Blum, MD, of Ohio State University in Columbus, Ohio.

 

 

 

Guiding Hematologic Care with Genetic Testing

Sunday, December 6, 7:30 a.m. - 9:00 a.m.
or
Monday, December 7, 10:30 a.m. - 12:00 p.m.

 

Presented by:

This session will look at precision medicine and the technologies used to detect DNA variants, and it will discuss the implications of using genetic information in clinical practice. Presenters are: Jill M. Johnsen, MD, of Bloodworks NW in Seattle, Washington; Paula D. James, MD, FRCPC, of Queen's University in Canada; and Rakhi P. Naik, MD, MHS, of Johns Hopkins University School of Medicine in Baltimore.

 

 

 

Impact of Genomes: How Well Are We Incorporating the Assessments of Actionable Results?

Sunday, December 6, 12:30 p.m. - 1:30 p.m.

Presented by:
Ross L. Levine, MD
Torsten Haferlach, MD

In this session, Ross L. Levine, MD, of Memorial Sloan Kettering Cancer Center in New York, New York, and Torsten Haferlach, MD, of the Munich Leukemia Laboratory in Munich, Germany, will share their perspectives on how the field has advanced in using genomic data to guide leukemia therapies in the U.S. and in Europe.

 

 

 

 

Presidential Symposium

Hematologic Diseases in the Post-Genome Era: New Insights, New Therapies, New Possibilities

Tuesday, December 8
9:45 a.m. - 11:15 a.m.

Presented by:
Mignon L. Loh, MD
Scott A. Armstrong, MD, PhD
Luigi Naldini, MD, PhD

 

During this presentation, Mignon L. Loh, MD, of Benioff Children’s Hospital, San Francisco, California; Scott A. Armstrong, MD, PhD, of the Memorial Sloan-Kettering Cancer Center in New York, New York;  and Luigi Naldini, MD, PhD of the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy will share insights gained in the study of childhood diseases and their impact on evolving therapies for adult hematologic disorders.

 

 

 

Tuesday, December 8
11:30 a.m. - 1:00 p.m.

Presented by:
Andrew W. Roberts, MBBS, PhD
Akiko Shimamura, MD, PhD


 

This session, led by Andrew W. Roberts, MBBS, PhD, of The Royal Melbourne Hospital in Parkville, Australia, and Akiko Shimamura, MD, PhD, of Boston Children's Hospital in Boston, will provide a review of the key themes from this year's meeting.

 

 

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.